1. Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
- Author
-
Li Wang, Markus H. Kainulainen, Nannan Jiang, Han Di, Gaston Bonenfant, Lisa Mills, Michael Currier, Punya Shrivastava-Ranjan, Brenda M. Calderon, Mili Sheth, Brian R. Mann, Jaber Hossain, Xudong Lin, Sandra Lester, Elizabeth A. Pusch, Joyce Jones, Dan Cui, Payel Chatterjee, M. Harley Jenks, Esther K. Morantz, Gloria P. Larson, Masato Hatta, Jennifer L. Harcourt, Azaibi Tamin, Yan Li, Ying Tao, Kun Zhao, Kristine Lacek, Ashley Burroughs, Wei Wang, Malania Wilson, Terianne Wong, So Hee Park, Suxiang Tong, John R. Barnes, Mark W. Tenforde, Wesley H. Self, Nathan I. Shapiro, Matthew C. Exline, D. Clark Files, Kevin W. Gibbs, David N. Hager, Manish Patel, Alison L. Halpin, Laura K. McMullan, Justin S. Lee, Hongjie Xia, Xuping Xie, Pei-Yong Shi, C. Todd Davis, Christina F. Spiropoulou, Natalie J. Thornburg, M. Steven Oberste, Vivien G. Dugan, SSEV Bioinformatics Working Group, David E. Wentworth, and Bin Zhou
- Subjects
Science - Abstract
Emerging SARS-CoV-2 variants raise concerns on immune evasion. Here, the authors evaluate the neutralization efficiency of COVID-19 mRNA vaccinee sera against representative viruses of 13 WHO-designated SARS-CoV-2 variants of concern/interest.
- Published
- 2022
- Full Text
- View/download PDF